The first of the current drugs approved for the treatment of Alzheimer’s disease (AD) was donepezil in 1996, followed in subsequent years by rivastigmine (2000) and galantamine (2001), all having the same mechanism of action by inhibiting acetylcholinesterase [1]. This evidence concerns the gene ACHE and Alzheimer disease.